Archives of gerontology and geriatrics · 2026
Anticholinergic burden on admission assessed by the Japanese Anticholinergic Risk Scale and incident in-hospital delirium in older adults: A multicenter prospective cohort study.
СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yamada Yosuke, Nakashima Hirotaka, Nagae Masaaki, Watanabe Kazuhisa, Fujisawa Chisato, Komiya Hitoshi, Tajima Tomihiko, Mizokami Fumihiro, Satake Shosuke, Takeya Yasushi, Yakabe Mitsutaka, Umegaki Hiroyuki
Аннотация
OBJECTIVES: To examine whether admission anticholinergic burden, quantified by the Japanese Anticholinergic Risk Scale (JARS), is associated with incident in-hospital delirium and whether baseline cognition modifies this association.
METHODS: In this prospective multicenter cohort (Japan; October 2019-March 2025), 987 adults aged ≥60 years admitted to acute geriatric wards at 3 university hospitals and 1 national medical center were assessed. JARS from admission medication reconciliation was modeled as 0, 1-2, and ≥3, and per 1-point increase. Delirium was diagnosed on ward rounds using DSM-5 criteria. Cognition was assessed by Mini-Mental State Examination (MMSE) and stratified as ≤23 vs ≥24. Logistic regression adjusted for age, sex, MMSE, emergency admission, Clinical Frailty Scale, Charlson Comorbidity Index, and C-reactive protein; effect modification was tested with a JARS×MMSE interaction and stratified models.
RESULTS: Delirium occurred in 156 participants (15.8%). JARS was 0 in 48.1%, 1-2 in 38.8%, and ≥3 in 13.1%. High burden (JARS ≥3) was associated with delirium (adjusted OR 1.76, 95% CI 1.09-2.85). Per 1-point higher JARS, the overall association was borderline (OR 1.13, 95% CI 1.00-1.27) but differed by cognition: OR 1.80 (1.27-2.56) for MMSE ≥24 and 1.06 (0.93-1.21) for MMSE ≤23 (interaction P=0.011-0.029).
CONCLUSIONS: This prospective multicenter study provides the first evidence supporting JARS-based delirium risk stratification, with a clearer dose-response among cognitively preserved patients. JARS-based medication review at admission may help target potentially preventable delirium risk in acute geriatric wards.
METHODS: In this prospective multicenter cohort (Japan; October 2019-March 2025), 987 adults aged ≥60 years admitted to acute geriatric wards at 3 university hospitals and 1 national medical center were assessed. JARS from admission medication reconciliation was modeled as 0, 1-2, and ≥3, and per 1-point increase. Delirium was diagnosed on ward rounds using DSM-5 criteria. Cognition was assessed by Mini-Mental State Examination (MMSE) and stratified as ≤23 vs ≥24. Logistic regression adjusted for age, sex, MMSE, emergency admission, Clinical Frailty Scale, Charlson Comorbidity Index, and C-reactive protein; effect modification was tested with a JARS×MMSE interaction and stratified models.
RESULTS: Delirium occurred in 156 participants (15.8%). JARS was 0 in 48.1%, 1-2 in 38.8%, and ≥3 in 13.1%. High burden (JARS ≥3) was associated with delirium (adjusted OR 1.76, 95% CI 1.09-2.85). Per 1-point higher JARS, the overall association was borderline (OR 1.13, 95% CI 1.00-1.27) but differed by cognition: OR 1.80 (1.27-2.56) for MMSE ≥24 and 1.06 (0.93-1.21) for MMSE ≤23 (interaction P=0.011-0.029).
CONCLUSIONS: This prospective multicenter study provides the first evidence supporting JARS-based delirium risk stratification, with a clearer dose-response among cognitively preserved patients. JARS-based medication review at admission may help target potentially preventable delirium risk in acute geriatric wards.